Price
CHART BY
Frequently asked questions
What is Beam's market capitalization?
The market capitalization of Beam is $2.58B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Beam?
Beam's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.86. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Beam's stock?
Currently, 16 analysts cover Beam's stock, with a consensus target price of $51.07. Analyst ratings provide insights into the stock's expected performance.
What is Beam's revenue over the trailing twelve months?
Over the trailing twelve months, Beam reported a revenue of $156.04M.
What is the EBITDA for Beam?
Beam's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$355.78M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Beam?
Beam has a free cash flow of -$372.77M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Beam have, and what sector and industry does it belong to?
Beam employs approximately 511 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Beam's shares?
The free float of Beam is 93.96M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.58B
- EPS (TTM)
- -$0.86
- Free Float
- 93.96M
- Revenue (TTM)
- $156.04M
- EBITDA (TTM)
- -$355.78M
- Free Cashflow (TTM)
- -$372.77M
Pricing
- 52W span
- $20.24$38.25
Analyst Ratings
The price target is $51.07 and the stock is covered by 16 analysts.
Buy
14
Hold
2
Sell
0
Information
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
- Employees
- 511
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BEAM
Fundamentals & EOD data from FactSet